AU · rank #18 · 2026-09-08
DSFIR
AMSTERDAM · EUR · $26.73B (USD)
The exact numbers the algorithm saw.
| Composite score Z-score blend of all factors below. | 0.901 |
|---|---|
| EPS revisions (30d) Change in consensus EPS estimate over the past 30 days ($/share). | +$0.08 |
| Net revisions (30d) Number of analysts revising upward minus downward. | 13 |
| Insider signal (90d) | — |
| Analyst upside Consensus target $93.67 | +0.2% |
| Momentum acceleration 3-month minus 12-month momentum. | +26.21% |
| Analyst rating 5 = Strong Buy, 1 = Strong Sell. | 4.05 |
| Gross margin TTM | +39.2% |
| 52w high | $96.74 |
| Market cap (USD) | $26.73B |
The AI research card
Independent qualitative review of each pick before the order is placed. On the rare day the research service is unavailable, the paper book trades on the quant ranking alone and no card appears here.
Summary
DSM-Firmenich is a specialty ingredients and solutions company serving food, nutrition, health and beauty markets through three focused business units following its exit from Animal Nutrition.
Rationale
100% analyst revision agreement, 20% consensus upside, and accelerating Q2 momentum (6% LFL growth, ~3% EBITDA beat, 12% share price reaction) collectively validate the analyst_upside signal as grounded in a genuine fundamental inflection rather than mere sentiment drift.
Material risks
- 1Vitamins and nutritional ingredient commoditization remains a live threat—lower-cost rivals can erode volumes and margins in segments where DSM-Firmenich's differentiation is weakest, directly undermining the margin expansion path to 22–23% EBITDA by 2028.
- 2The 53% analyst target dispersion is unusually wide for a €27B cap name, signaling deep disagreement on synergy delivery and ANH divestment proceeds, meaning any execution stumble on the €500M synergy program could trigger sharp consensus downgrades.
AI verdict council
Each pick is reviewed independently by 3 models before any order. 3 of 3 voted to proceed.